AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
AVITA Medical, Inc.NASDAQ: RCEL
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $24.53M fell 10.8% year over year, ahead of the -12.5% change in trailing-twelve-month operating expenses. Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at +21.7% a year.
Context
- Operating expenses amounted to 140.7% of revenue in FY2025, down 33.2 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -10.8% holds above the trailing-twelve-month pace of -12.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 100.75M USD
- Year-over-year change
- -9.8%
- 4-year CAGR
- +18.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100.75M | -9.8% |
| FY2024 | 2024-12-31 | 111.75M | +31.4% |
| FY2023 | 2023-12-31 | 85.02M | +52.1% |
| FY2022 | 2022-12-31 | 55.89M | +7.4% |
| FY2021 | 2021-12-31 | 52.04M | — |
Operating Expenses vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's LTM Mar 2026 operating expenses of $98.38M is the highest of the 9 companies compared; the peer median is $44.9M.
- Its year-over-year change of -12.5% is the 6th highest of 9, against a peer median of -6.2%.
- Operating expenses amounts to 136.0% of revenue for RCEL, versus a peer median of 277.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $98.38M | -12.5% | +21.7% | 136.0% | |
| LTM Mar 2026 | $72.7M | -7.6% | +25.6% | 59.6% | |
| LTM Mar 2026 | $54.82M | -4.8% | -4.7% | 769.8% | |
| LTM Mar 2026 | $51.84M | -32.4% | +34.1% | 5184.4% | |
| LTM Mar 2026 | $47.21M | +5.1% | -4.0% | 919.6% | |
| LTM Mar 2026 | $42.59M | -12.9% | -16.3% | 277.8% | |
| LTM Mar 2026 | $32.88M | +8.0% | +7.8% | 31.2% | |
| LTM Mar 2026 | $27.68M | +11.1% | +8.5% | — | |
| LTM Mar 2026 | $22.35M | -43.7% | -21.5% | 40.0% | |
| Peer median (excluding RCEL) | $44.9M | -6.2% | +1.9% | 277.8% | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.03M | 34.42M | 50.14M | 64.25M | 71.61M |
| Cost of Revenue | 6.1M | 6.04M | 7.78M | 9.09M | 12.79M |
| Gross Profit | 26.92M | 28.38M | 42.36M | 55.16M | 58.82M |
| Gross Margin | 81.5% | 82.4% | 84.5% | 85.8% | 82.1% |
| Research & Development | 15.67M | 13.86M | 20.82M | 20.36M | 20.84M |
| Selling, General & Admin | 37.21M | 45.24M | 65.63M | 91.39M | 79.91M |
| Operating Expenses | 52.04M | 55.89M | 85.02M | 111.75M | 100.75M |
| Depreciation & Amortization | 673K | 568K | 632K | 1.13M | 2.35M |
| EBITDA | (24.4M) | (26.05M) | (33.54M) | (55.3M) | (39.59M) |
| EBITDA Margin | -73.9% | -75.7% | -66.9% | -86.1% | -55.3% |
| Operating Income | (25.12M) | (27.51M) | (42.66M) | (56.59M) | (41.93M) |
| Operating Margin | -76.1% | -79.9% | -85.1% | -88.1% | -58.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 29K | 16K | 1.14M | 5.36M | 5M |
| Other Income / Expenses | 18K | 876K | 7.34M | (5.2M) | (6.64M) |
| Income Before Tax | (25.1M) | (26.63M) | (35.32M) | (61.79M) | (48.58M) |
| Pre-Tax Margin | -76.0% | -77.4% | -70.4% | -96.2% | -67.8% |
| Income Tax Expense | 42K | 36K | 66K | 54K | 11K |
| Net Income | (25.14M) | (26.67M) | (35.38M) | (61.85M) | (48.59M) |
| Net Margin | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% |
| EPS (Basic) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| EPS (Diluted) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| Weighted Avg Shares | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
| Weighted Avg Shares (Diluted) | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.